Next Science Ltd (AU:NXS) has released an update.
Next Science Limited has announced successful results from a study indicating that their BLASTX™ product enhances the effectiveness of Negative Pressure Wound Therapy in treating pressure ulcers, as published in the peer-reviewed journal Diagnostics. The research, which observed a significant reduction in bacterial levels and wound size, supports Next Science’s commitment to advancing treatments for biofilm-based infections. This breakthrough aligns with the company’s focus on commercializing its XBIO™ technology to improve patient health outcomes.
For further insights into AU:NXS stock, check out TipRanks’ Stock Analysis page.
